Kartesia, the European specialist provider of capital solutions for small and mid-sized companies, is pleased to announce that it has provided a financing package to support Avedon Capital Partners (“Avedon”) in the acquisition of FormMed HealthCare AG (“FormMed” or “the Company”).
Headquartered in Frankfurt, Germany, FormMed is a leading provider of micronutrient supplements, which are used as therapy for patients for specific health conditions. The Company’s portfolio comprises over 400 premium quality supplements for more than 250 symptoms and follows a unique distribution model via its network of c.3,500 affiliated nutritional specialists, therapists, and doctors. FormMed collaborates closely with its partner network in the development of new products and drives innovation for nutritional supplements via integrated systems to track the effectiveness of new therapies. The Company scores highly on ESG parameters, since FormMed, as a first mover in the micronutrition supplements space, is at the forefront of driving the acceptance of scientifically based nutritional supplements and adoption of a healthy lifestyle.
Kartesia has supported Avedon with a Unitranche loan to finance the acquisition of shares in the Company. The capital for this investment is provided by Kartesia Senior Opportunities (“KSO”) Funds I & II. The deal team at Kartesia included Sebastian Afflerbach, Kristina Ivanova and Rok Kejzar.
Sebastian Afflerbach, Investment Manager at Kartesia, said: “We are excited to support Avedon in this transaction. FormMed’s business model and position in the wider healthcare space and its role in the promotion of a healthy lifestyle perfectly matches our investment criteria. Based on its strong value proposition and unique distribution model, together with Avedon’s existing expertise in consumer health and strategically growing businesses internationally, we are convinced that the company will continue its impressive growth trajectory. We look forward to working with Avedon and the management team in driving the continued success of FormMed.”
Philip Fischer, Investment Director at Avedon: “We are very pleased to have found Kartesia as a partner for this transaction, who were able to provide us with various innovative structural alternatives throughout the process. Their straightforward, pragmatic approach and swift execution capabilities where a big value add in securing financing for the deal. We are delighted to have worked with Kartesia on this transaction and look forward to further growing our partnership in the future.”